Antimicrobial peptides are a promising complement to common antibiotics, development of resistance to which is a growing problem. Here we present a de novo-designed peptide, SP1-1 (RKKRLKLLKRLL-NH 2 ), with antimicrobial activity against multiresistant Staphylococcus aureus (minimal inhibitory concentration: 6.25 M). Elucidation of the mode of action of this peptide revealed a strong interaction with RsbW kinase (K d : 6.01؎2.73 nM), a serine kinase negatively regulating the activity of the transcription factor B (SigB). SP1-1 binding and functional modulation of RsbW were shown in vitro by a combination of biochemical, molecular, and biophysical methods, which were further genetically evidenced in vivo by analysis of S. aureus ⌬sigB deletion mutants. Intracellular localization of the peptide was demonstrated using nanometer-scaled secondary ion mass spectrometry. Moreover, microarray analysis revealed that transcription of numerous genes, involved in cell wall and amino acid metabolism, transport mechanisms, virulence, and pigmentation, is affected. Interestingly, several WalR binding motif containing genes are induced by SP1-1. In sum, the designed peptide SP1-1 seems to have multiple modes of action, including inhibition of a kinase, and therefore might contribute to the development of new antibacterial compounds, giving bacterial kinase inhibition a closer
Antimicrobial peptides (AMPs) belong to the most ancient molecules in pathogen defense. They are part of the innate immunity and play an important role in the first line of defense in a widespread multitude of higher organisms throughout the phylogenetic tree, including invertebrates, plants, and animal species (1) (2) (3) . AMPs are effective weapons against a broad variety of invading pathogens (4, 5) . Since the discovery of cecropins from pupae of the moth Hyalophora cecropia (6) and magainins in the skin of African claw frogs (7) as the first antimicrobial peptides in the 1980s, discovery of several hundred molecules belonging to different structural groups and origins has followed (8, 9) .
In general, AMPs are composed of 10 to 50 aa, and their most important feature is their amphipathic character (10) . High portions of basic amino acids such as lysine and arginine result in a positive net charge of ϩ2 to ϩ7. Furthermore, these molecules often possess up to 50% hydrophobic residues. Within the group of cationic AMPs, there are also a number of different known structural models; the most prominent examples are ␣-helical and ␤-sheet structures. Other structural groups include peptides with ring structures or peptides with irregular amino acid composition (11) .
Their structural and physicochemical differences result in different modes of action. Over the past few decades, it has been assumed that antimicrobial peptides mainly attack the cell membrane of pathogens, since prokaryotic membranes exhibit a negative net charge. However, it is known from several examples that the first interaction by electrostatic attraction does not necessarily lead to an influence of membrane integrity. There are also known peptides that translocate through the membrane after their first contact and interact with intracellular targets, such as nucleic acids. This results in inhibition or alteration of DNA replication and transcription or mRNA translation, as has been demonstrated for Buforin II (12) . For p-Der, an amidated hybrid of the flounder pleurocidin and the frog dermaseptin, inhibition of RNA and DNA synthesis was reported in E. coli (13) . Effect on intracellular proteins and enzymes has also been described. The antimicrobial peptide pyrrhocoricin inhibits the ATPase action of the bacterial heat-shock protein DnaK and thereby prevents chaperone-assisted protein folding (14) . In addition, activating effects on the immune system of the infected host have been shown for a number of peptides, including LL-37, which induces chemotactic effects (15) . Even cumulative effects by acting on multiple targets have been discussed (5, 16) .
Bacterial resistance against antibiotics is a growing problem worldwide and gives need for development of new antimicrobial agents (17, 18) . Staphylococcus aureus is an especially problematic pathogen, since it has a high ability to acquire resistance. It can cause severe infections, including pneumonia, boils, abscesses, wound infections, endocarditis, osteomyelitis, and sepsis (19) . Since 1940, several waves of resistance have been discovered, and until now the number of nosocomial infections caused by such methicillin-resistant S. aureus (MRSA) strains constantly has increased. Most clinical MRSA strains are resistant to antibiotics of different classes. Additional outbreaks and epidemics of community-acquired MRSA occur worldwide (20) . Meanwhile, many of these MRSA strains also acquired resistance against vancomycin, the last remaining antibiotic to combat them. Therefore, tools for fighting these pathogens are becoming rare. Considering the increasing number of MRSA infections (Ͼ500,000/yr in the United States) and cases of death (Ͼ20,000/yr in the United States), the therapy of such severe infections are a medical challenge and a financial burden for hospitals (18) . AMPs often have multiple modes of action and often very general targets, such as membranes or DNA. This might be the reason why the levels of resistance to naturally occurring AMPs have remained very low. Thus, they are promising alternatives to conventional antibiotics, which often have very distinct targets (10) .
Based on the ␣-helical structure of naturally occurring AMPs, we previously designed peptides that can be separated into 4 groups differing in size and location of cationic and hydrophobic amino acid clusters. Several of our de novo-designed peptides showed antimicrobial activity against clinical isolates of MRSA strains. Interestingly, peptide SP1-1 interacts strongly with the serine protein kinase RsbW of S. aureus in vitro, which is a negative regulator of the B regulon. The interaction with the kinase results in inhibition of this enzyme. Moreover, translocation of SP1-1 into the bacteria cells could be demonstrated by nanometer-scale secondary ion mass spectrometry (nanoSIMS), suggesting that inhibition of RsbW could be a mode of action of this peptide. Therefore, peptide SP1-1 might serve as a very promising candidate for further studies to develop bacterial kinase inhibitors.
MATERIALS AND METHODS

Peptides
Designed peptides were synthesized by Hanhong Chemical Co. (Shanghai, China).
15 N-labeled 15 N-SP1-1 was synthesized by Genscript (Piscataway, NJ, USA). All peptides were purchased with C-terminal amidation and with a purity of Ͼ80%. Peptides were dissolved in sterile filtered water or peptide dilution buffer (0.01% acetic acid and 0.2% bovine serum albumin; Sigma-Aldrich, Munich, Germany) at a concentration of 1 mg/ml, and stored at Ϫ20°C.
Microorganisms
Bacterial strains used included S. aureus 90857 (Max von Pettenkofer Institute of Hygiene and Medical Microbiology, Ludwig Maximilian University, Munich, Germany), S. aureus COL, S. aureus RN1HG, S. aureus RN1HG ⌬sigB, and S. aureus RN1HG ⌬sigB complemented (Institute of Microbiology, Ernst Moritz Arndt University of Greifswald, Greifswald, Germany). Bacteria were stored in 20% glycerol at Ϫ80°C. Bacteria were grown in brain-heart infusion (BHI) or lysogeny broth (LB) at 37°C.
Antibacterial assay
Microbroth dilutions assays were performed in sterile flat bottom 96-well plates (Greiner-bio-one, Frickenhausen, Germany). Dilutions of peptides (10-fold concentration of final assay concentration) were prepared in peptide buffer (0.2% BSA and 0.01% acetic acid), and 10 l of each dilution step was loaded per well. Bacteria from fresh agar plates were taken with an inoculation loop and suspended in LuriaBertani broth medium. The OD 600 nm was measured, and the suspension was diluted to 1.1 ϫ 10 6 CFU/ml. Next, 90 l of this bacterial suspension was loaded to each well, resulting in 10 5 CFU/well and final peptide concentrations from 0 to 62.5 M. Peptide buffer (10 l) without added peptide served as control. After 20 h incubation at 37°C, OD 600 nm was determined with a Tecan Genios microplate reader (Tecan, Crailsheim, Germany). Minimal inhibitory concentrations (MICs) were determined. MIC is defined as the lowest concentration (micromolar) of the AMP that prevents visible growth after incubation time (21) . The antimicrobial tests were performed in duplicate.
Bacterial growth and microarray experiments
The experiment was performed based on a protocol of Pietiäinen et al. (22) with modifications. S. aureus COL from an overnight culture in BHI medium was diluted to OD 600 nm 0.05 and grown at 37°C to exponential phase (OD 600 nm 0.6), and 1.8-ml cultures were treated with either 200 l of SP1-1 in a sublethal concentration of 4 g/10 6 CFU in peptide buffer (0.2% BSA, 0.01% acetic acid) or the same amount of buffer (mock treatment). Cells were grown for further 10 min and harvested by centrifugation (10 min, 4000 g, 4°C). Cell pellets were resuspended in 500 l acetone:ethanol (1:1, v/v) and stored at Ϫ80°C until RNA purification. Sublethal concentrations were determined by measurement of OD 600 nm values 5, 10, 30, 50, and 120 min after treatment of 200-l cultures at OD 600 nm of 0.6 with peptide concentrations of 0, 1, 2, 4 g/10 5 CFU. The microarray was manufactured by in situ synthesis of 10,807 60-mer long oligonucleotide probes (Agilent, Palo Alto, CA, USA), selected as described previously (23) . It covered Ͼ95% of all open reading frames (ORFs) annotated in strains N315 and Mu50 (24), MW2 (25) and COL (26) , NCTC8325 (27) , USA300 (28), MRSA252 and MSSA476 (29) , and Newman (30) including their respective plasmids. Extensive experimental validation of this array has been described previously, using comparative genomic hybridization (CGH), mapping of deletion, specific PCR, and quantitative RT-PCR (23) .
Total RNA was extracted as described previously (31) . DNA-free total RNA was obtained after DNase treatment onto RNeasy columns (Qiagen, Hilden, Germany). The absence of remaining DNA traces was evaluated by quantitative PCR (Mx 3005; Agilent) with assays specific for 16s rRNA (31) . Preparations of 5 g total S. aureus RNA were labeled by Cy-3 dCTP using the SuperScript II method (Invitrogen, Basel, Switzerland) and purified as described previously (31) . Purified genomic DNA from the reference sequenced strains used for the design of the microarray was labeled with Cy-5 dCTP (23) and used in microarray normalization. Mixtures of Cy5-labeled DNA and Cy3-labeled cDNA were hybridized and scanned as described previously (31) .
Fluorescence intensities were extracted using the Feature Extraction 8 software (Agilent). Local background-subtracted signals were corrected for unequal dye incorporation or unequal load of labeled product. The algorithm consisted of a rank consistency filter and a curve fit using the default LOWESS (locally weighted linear regression) method. Data from 3 independent biological experiments were analyzed using GeneSpring 8.0 (Silicon Genetics, Redwood City, CA, USA) as described previously (31) with a 5% P value cutoff (PϽ0.05) and an arbitrary threshold of 3-fold for defining significant differences in expression ratios. The complete microarray dataset is posted on the U.S. National Center for Biotechnology Information (NCBI; Bethesda, MD, USA) Gene Expression Omnibus database (http://www.ncbi.nlm. nih.gov/geo/), with accession number GPL7137 for the platform design and GSE1207 for the original dataset.
Yeast 2-hybrid (Y2H) library and peptide coding plasmid construction
A Y2H library representing almost every S. aureus gene was produced using a pool of PCR products (32) . First, the pool of 2697 PCR products, each flanked with attB1 and attB2 sites for recombinational cloning or Gateway cloning (Invitrogen; refs. 33, 34) , was recombined into the Gateway-compatible pDONR/Zeo (Invitrogen) vector by attB ϫ attP recombination using 450 ng PCR product, 300 ng pDONR/Zeo plasmid, 2 l BP Clonase II Enzym Mix (Invitrogen), and TE buffer (pH 8.0) up to 10 l. The reaction was incubated overnight at 25°C.
After adding 1 g proteinase K solution (Invitrogen) at 37°C for 30 min, 3 l of the reaction was used directly for bacterial transformation. The resulting 0.5 ϫ 10 6 individual colonies were cultured and plasmid isolated using the GenElute HP Plasmid Maxiprep Kit (Sigma-Aldrich, St. Louis, MO, USA). As the second step in the Y2H prey Library construction, 800 ng of the created library in pDONR/Zeo was recombined by attL ϫ attR reaction (34) into 300 ng of the Gateway-compatible pAD-Gate2 vector (35) by adding 2 l LR Clonase II Enzyme Mix (Invitrogen) and TE buffer (pH 8.0) up to 10 l. The reaction was stopped with proteinase K solution and directly used for bacterial transformation. Overall, 1.1 ϫ 10 6 primary colonies were cultured and subsequently used for plasmid isolation using the GenElute HP Plasmid Maxiprep Kit.
As bait plasmid, coding peptide sequnces (SP1-1 or SP10-2) were cloned by recombination into the Y2H Destination vector pBD-Gate2 (35) . The SP1-1 sense oligonucleotide (5=-ATGAGAAAGAAGAGACTTAAGCTTCTTAAGAGATT-GCTTTGA-3=) was annealed with the respective antisense oligonucleotide (5=-TCAAAGCAATCTCTTAAGAAGCTTAAGTC-TCTTCTTTCTCAT-3=) and cloned into an in-house-created Entry vector designed for Gateway cloning (pENTRY Zeo/ ScaI). The same was done for SP10-2 sense (5=-ATGTTGAGG-TTCCTTAAGAAGGCTCTTAAGAAGCTTTTCTGA-3=) and antisense (5=-TCAGAAAAGCTTCTTAAGAGCCTTCTTA-AGGAACCTCAACAT-3=) oligonucleotides. The pENTRY Zeo/ScaI vector harbors the blunt-end restriction site ScaI between the attL1 and the attL2 site. After transformation and plasmid preparation, positive clones were sequenced. One positive SP1-1 and one SP10-2 clone in pENTRY/Zeo/ ScaI were then used for attL ϫ attR recombination (34) into pBD-Gate2 using the LR Clonase II Enzyme Mix Kit (Invitrogen) according to the kit manual. After transformation, a positive selected clone was subjected again for sequencing and for plasmid preparation using the GenElute HP Plasmid Maxiprep Kit.
Standard Y2H analysis, Y2H screen, and quantification of protein-protein interactions (PPIs)
For single Y2H PPI analysis, bait and prey vectors were transformed together into the haploid yeast strain AH109 (MAT␣) from the Matchmaker Two-Hybrid System (Clontech, Mountain View, CA, USA) according to the kit manual. Half of each transformation was plated onto selective plates deficient in leucine and tryptophan (SD/ϪleuϪtrp) to test for positive transformation and half on a nutritionally selective plate deficient in leucine, tryptophan, adenine, and histidine (SD/ϪleuϪtrpϪadeϪhis) to test for the putative interaction. The plates were incubated for at least 5 d at 28°C. To exclude autoactivity of the examined bait and prey combinations, each prey plasmid was cotransformed with empty pGBKT7 vector and each bait plasmid with empty pGADT7 vector (both Clontech) and examined in the same way.
Direct plating of transformants onto PPI-selective SD/ ϪleuϪtrpϪadeϪhis medium represents a stringed condition, which permits only yeast cells with strong interactors to grow. Therefore, we also analyzed all transformants under less stringent conditions to detect possible weak interactions and exclude spurious autoactivity. After growing the yeast colonies on SD/ϪleuϪtrp plates, several random colonies were picked, resuspended in water, dropped out, and grown on SD/ϪleuϪtrp and SD/ϪleuϪtrpϪadeϪhis media.
A large-scale Y2H screen was performed by the cotransformation of 180 g SP1-1 or SP10-2 in pBD-Gate2 together with 180 g S. aureus ORF library in pAD-Gate2 in an up-scaled yeast transformation protocol. Finally, a part of the transformation was plated onto one SD/ϪleuϪtrp plate to test for positive plasmid uptake and general transformation efficiency and on SD/ϪtrpϪleuϪadeϪhis plates to screen for novel PPIs. The plates were incubated for at least 5 d at 28°C. The grown primary positive yeast candidate clones were recovered by plasmid isolation via digestion with 10 U lyticase (SigmaAldrich), addition of 10% SDS, 1 freeze-thaw cycle, and purification by using a Wizard SV gel and PCR clean-up system (Promega, Madison, WI, USA). The plasmids were then amplified in Escherichia coli DH5␣ cells, sequenced, and reintroduced back into the yeast strain AH109 to verify the putative interaction.
For quantification of the PPI Y2H clones from transformation, selective plates were cultivated in liquid SD/ ϪleuϪtrp overnight at 28°C with gentle shaking and analyzed for ␤-galactosidase activity. The cultures were diluted to OD 600 nm of 0.1, an equal volume of ␤-Glo Reagent (Promega) was added, and the mixture was incubated for 1 h at room temperature (3 replicates each). Luminescence counts were detected with a luminescence reader, the Paradigm detection platform (Molecular Devices, Sunnyvale, CA, USA).
Fluorescence polarization (FP)
FP assays were performed in pure water in 80 l reaction volumes in triplicates each using 20 nM fluorescein isothiocyanate (FITC)-labeled SP1-1 (chemically synthesized by GenScript, Piscataway, NJ, USA) per black-bottomed microtiter plate well (Nalge Nunc, Rochester, NY, USA) plus increasing concentrations of recombinantly expressed and purified Strep-tagged RsbW kinase in relation to an analogously treated specificity control (lysozyme). 
Production of recombinant RsbW, RsbV, and transcription factor B (SigB)
Coding sequences of RsbW, RsbV and SigB, cloned into BsaI restriction site in plasmid pPR-IBA1 were transformed, expressed, and purified as described previously (36) . The plasmid was transformed into E. coli BL 21 (DE3) plys S and used to inoculate LB medium (35 g/ml Cm and 100 g/ml Amp) to an OD 600 nm of 0.05. After reaching an OD 600 nm of 0.5, protein expression was induced (1 mM IPTG), and after a further 2.5 h of growth at 37°C, the cells were harvested by centrifugation. Cell lysis was done by thawing bacterial cell pellets for 10 min on ice and subsequently resuspending in lysis buffer (RsbW/RsbV: 50 mM KCl, 50 mM Tris, 2 mM MgCl 2 , 1 mM DTT, pH 8; SigB: 150 mM NaCl, 100 mM Tris, 1 mM EDTA, 1 mM DTT, pH 8) with 1 mg/ml Lysozym. After incubation on ice for 30 min, 10 g/ml RNase A and 5 g/ml DNase I were added, and cell disruption was further propagated by 6 ϫ 10-s bursts of ultrasonication with 10 s cooling between each burst. After 15 min of incubation on ice, cell debris was removed by centrifugation (12, 000 g, 30 min, 4°C) . The plasmid was affinity purified using strep tactin superflow plus 1 ml catrige (IBA, Göttingen, Germany), and RsbW was additionally gel filtered with a superdex 75 (GE Healthcare, Freiburg, Germany). Purification was carried out following the manufacturer=s instructions with an Ä kta Explorer 10 liquid chromatography system, equipped with a Frac-901 fraction collector and operated by Unicorn 5.11 control software (GE Healthcare).
In vitro RsbW binding and phosphorylation inhibition by SP1-1
The inhibition of RsbV phosphorylation and the inhibition of the RsbW-SigB complex formation were analyzed. Synthetic peptide (0.5-8 g) was preincubated with 0.1 M RsbW in for 15 min at room temperature. RsbV or SigB (in a molar ratio RsbV/RsbW of 1:1 or SigB/RsbW of 1:2) was added, and phosphorylation of RsbV (by subsequent addition of 1 mM ATP) or complex formation with SigB was carried out by incubation at room temperature for a further 5 min. The reactions were stopped by adding 50 mM EDTA (pH 8.0) and incubating on ice. Then the samples were applied to 15% native PAGE and stained with Coomassie protein stain.
In vivo test for RsbW inhibition by SP1-1 in S. aureus sigB-deletion mutants
To test the possibility of RsbW as target for SP1-1 in vivo and to analyze whether the inhibition of this enzyme can be the mode of action of SP1-1 under physiological conditions, antimicrobial activity tests with S. aureus mutant strains were performed. S. aureus strain RN1HG (wild type; ref. 37), the deletion mutant ⌬sigB (rsbU and the rsbW-, rsbV-, sigB-containing operon sigB are deleted), and an episomally generated complemented mutant strain (⌬sigB complemented) were used. Microbroth dilution assays were done with different concentrations of peptides (0, 0.5, 5, 10, 40, or 100 g/ml). Bacterial growth of the different strains was monitored by measuring the OD 600 nm after 18 h of SP1-1 treatment. The strains were tested for antibacterial activity of SP1-1 as described above. Peptides SP8 and SP10-2 served as controls. The OD 600 nm and MIC values were measured after 18 h and compared between the 3 strains.
NanoSIMS experiments
S. aureus cells (clinical isolate 90857) were grown in BHI medium overnight, diluted in the same medium, and grown to midlogarithmic phase, and an amount of 4 ϫ 10 6 CFU was treated with 0 (mock treatment) or 62.5 M 15 N-SP1-1. After 10 and 30 min, cells were harvested by centrifugation, and the pellet was resuspended in 6 ml PBS (1% paraformaldehyde) for fixation. Fixing and filter preparation were carried out after the protocol of Musat et al. (38) , with slight modifications. The mixture was fixed by incubation at 4°C, and cells were pelleted again and washed 3 times with PBS. The sample was resuspended in 100 l 50% PBS and 40% glycerol (v/v), and filtered on polycarbonate filters (GTTP type, pore-size 0.22 m, diameter, 13 mm; Millipore), previously sputtered for 5 min (ϳ40-nm layer) with gold (80%) and palladium (20%) to avoid charging effects. Filtering was done by using a dot blotter with dot diameter of 3 mm (Carl Roth GmbH & Co., Karlsruhe, Germany) by application of vacuum. The samples were air dried and fixed with copper adhesive foil on
of 60% at M/⌬M ϭ 5000 (39, 40) . Simultaneously, 7 different secondary ion species can be detected; the detection limit is in the parts per million or, for some elements, the parts per billion range (41 
RESULTS AND DISCUSSION
Antimicrobial activity of de novo-designed peptides
Antimicrobial peptides are a promising complement to conventional antibiotics. Previously, we designed peptides, several of which were active against different plant pathogens. In brief, the peptides were designed based on the typical features of naturally occurring AMPs. A helical structure was used a skeletal backbone for the peptides since many natural peptides have such a conformation. We selected a derivative of the scorpionderived antimicrobial peptide IsCT (12/13-aa peptides; Protein Data Bank code 1T52) and the frog-derived peptide magainin II (for 20-aa peptides; Protein Data Bank code 2MAG) as templates. The mutation tool of the SWISS-Pdbviewer software (http://spdbv.vital-it.ch/) was used to modify the template molecules and to design new peptides. The software enables one to see directly the 3-dimensional structure of the designed peptides (peptide model). In addition, the helical structure clusters of hydrophobic and positively charged amino acids are typical features of AMPs. A positive net charge of the designed peptides was guaranteed by using arginine, lysine, and histidine residues in the sequence. Leucine, isoleucine, valine, phenylalanine, and alanine residues were used to generate hydrophobic regions. A helical structure of the peptides was ensured by inserting strong helix-forming amino acids, such as leucine and alanine. The carboxyl termini of the designed peptides were amidated, since this modification generally enhances the structural stability and antimicrobial activity or decreases the cytotoxicity of antimicrobial peptides (42).
Here we tested their antimicrobial activity against the clinical isolate 90857 of S. aureus (Fig. 1) . This strain displays resistance against many common antibiotics, including penicillin, oxacillin, erythromycin, clindamycin, gentamicin, amikacin, ciprofloxacin, and moxifloxacin. Altogether, 29 peptides were tested against this strain (Fig. 1) . Peptide dilutions were incubated with bacterial cells for 20 h, and the MICs, defined as the lowest concentration of the AMP that prevents detectable growth (21), were determined. Especially (Fig. 1) and are more active against S. aureus than peptides based on natural structures, such as BmKbpp (43), GF-17 (44), or hPAB-␤ (45). These peptides have an MIC of ϳ60 M. Hemolytic activity of the designed peptides was determined as peptide concentration resulting in 50% hemolysis of human erythrocytes (Fig. 1) . No hemolysis was detectable for SP1 and its derivatives in the tested range up to 125 M. In contrast, several peptides of the SP10 and SP13 series showed moderate to high hemolytic activity (8 to Ͼ125 M).
Peptide SP1-1 interacts with RsbW kinase
Due to its negative net charge, a prokaryotic membrane is a preferred target for cationic antimicrobial peptides (46) . However, we focused our research on intracellular targets. Because of their physicochemical features, our designed peptides can bind to hydrophobic or negatively charged regions of proteins and enzymes and alter their function or activity. A Y2H screen was performed to screen for peptide-interacting proteins. Peptide SP1-1 and peptide SP10-2, which are among our most active peptides against S. aureus, were used as bait.
Seven positive colonies were identified in the initial genome-wide Y2H screening. However, only one candidate could be reproduced and verified for specificity in repeated direct Y2H experiments including appropriate controls ( Fig. 2A) . Sequence analysis revealed that this clone encodes for a serine protein kinase, RsbW. A liquid ␤-galactosidase activity assay was used to confirm the growth results and quantify the relative interaction strength (Fig. 2B) . ␤-Galactosidase activity of yeast cells tested for SP1-1/RsbW interaction corresponded to 45% of the positive control (mouse p53 and SV40 large T antigen) indicating a high affinity of SP1-1 to RsbW kinase (Fig. 2B) . To exclude autoactivation of bait and prey combinations from the Y2H screen, each prey plasmid was cotransformed with empty pGBKT7 vector and each bait plasmid with empty pGADT7 vector. The interaction was quantified by determining the ␤-galactosidase activity. A high ␤-galactosidase activity could only be detected when SP1-1 plasmid was combined with the RsbW plasmid, excluding an autoactivation of the vector systems (Fig. 2C) .
In addition, a standard FP measurement was performed to further confirm definite binding and to quantify the affinity between SP1-1 and RsbW kinase. The FP assay is a homogeneous, real-time format in vitro assay conceptually based on rotational differences between free SP1-1 vs. complexed SP1-1. A K d value of 6.01 nM Ϯ 2.73 nM was observed by the titration of constant amounts of FITC-labeled SP1-1 against increasing molarities of recombinant Strep-tagged RsbW kinase (after subtraction of unspecific binding from control proteins; Fig. 2D, E) . These data were further corroborated in an indirect competition assay to exclude FITC label influence. Therefore, unlabeled SP1-1 was used as competitor and titrated for IC 50 determination and indirect K d determination, which resulted in a comparable K d value of 6.38 nM. Taken together, peptide SP1-1 shows an extremely high affinity to the RsbW kinase, which is comparable even to many antibody-antigen interactions. Inhibition of enzyme functions was discovered as mode of action for several antimicrobial peptides, like proline-rich peptides from various insect species or salivary histatins eNAP-2 (47, 48).
SP1-1 inhibits activity of RsbW kinase
The identified interaction partner of SP1-1 is a serine kinase with an important role as a regulatory element of the alternative transcription factor SigB. This regulatory system is conserved in many bacteria, including S. aureus, Bacillus subtilis, and Mycobacterium tuberculosis (49 -51) . In its active homodimeric form, RsbW acts as an anti-factor (52). This anti-factor binds to SigB, preventing the complex formation between SigB and the RNA polymerase core enzyme. In this way, transcription of downstream genes is blocked. In addition, RsbW can perform partner switching (51) . Its binding to SigB is competed by the binding to RsbV, the substrate of RsbW kinase (36) . As soon as RsbV is phosphorylated, the binding to RsbW is inhibited, which in turn leads to decreased SigB activity. We analyzed whether SP1-1 influences the activity of RsbW kinase. Phosphorylation of RsbV alters its isoelectric point and molecular structure and results in higher electrophoretic mobility than the unmodified protein.
Recombinant RsbW kinase and its substrate RsbV was incubated with different concentrations of SP1-1 and analyzed by native PAGE (Fig. 3A) . Dose-dependent inhibition of the enzymatic reaction could be detected for SP1-1. With increasing concentrations of SP1-1, the band of RsbV-P became weaker, and nonphosphorylated RsbV was visible, demonstrating the inhibition of the phosphorylation reaction. Furthermore, the protein band corresponding to free RsbW disappeared with addition of Ͼ1 g of SP1-1, and the band corresponding to the RsbW-RsbV complex became slightly weaker. Peptide SP8, which is not active against S. aureus, could not inhibit RsbW phosphorylation activity a Peptide concentrations leading to 50% hemoglobin release (HC 50 ) from human blood cells. Ͼ125 describes a slight hemolytic activity at 125 m, which is below the above-mentioned threshold; dash indicates no hemolytic activity detectable up to the highest concentration tested (125 m).
b Estimated using the program Vector NTI 9.1 (Invitrogen ( Fig. 3A) . In addition, the effect of SP1-1 on the interaction of RsbW and the transcription factor SigB was analyzed (Fig. 3B ). After preincubation with peptide SP1-1, the intensity of the upper band indicating the RsbW-SigB-complex decreased, while the lower band representing the free RsbW kinase disappeared. The binding of SP1-1 probably leads to aggregation of RsbW kinase, resulting in inhibition of the phosphorylation activity and diminished formation of RsbW-SigB complexes. In contrast, SP8 did not interfere with the kinase, and the intact RsbW-SigB complex could be detected on the gel (Fig. 3B) .
To analyze the relevance of the influence of SP1-1 on RsbW in vivo, antibacterial activity tests were carried out with S. aureus RN1HG wild-type, sigB-deletion mutant strains (⌬sigB), and a complemented mutant (⌬sigB complemented). In the mutant strain, the sigB operon, which contains the genes encoding for RsbW kinase, for the substrate RsbV, and for the transcription factor SigB, was deleted (53, 54) . Bacterial were incubated with different concentrations of SP1-1, and growth of the different bacteria strains was monitored by measuring the OD 600 nm after 18 h (Fig. 3C) . The wild-type strain and the complemented mutant were inhibited by SP1-1 to 90%. In contrast, the growth of the ⌬sigB deletion mutant was only slightly affected (Fig. 3C) . These results indicate an influence of SP1-1 on the kinase RsbW in vivo. Surprisingly, SP1-1 showed a 10-fold higher MIC value than for S. aureus 90857. But SP10-2 also showed a 5-fold lower activity against RN1HG in comparison with the strain 90857, demonstrating that this strain might be generally more resistant to the peptides than strain 90857.
Some AMPs have already been reported to interact with intercellular targets. Buforin II, for example, is a very potent derivative of an antimicrobial peptide, isolated from the stomach tissue of the Asian toad Bufo bufo gargarizans (55) . It penetrates the cell membrane of E. coli without having lytic effects. It binds to DNA and RNA, indicating the inhibition or alteration of intracellular functions like DNA replication, transcription, or translation as a killing mechanism (12) . For pleuricidin, an AMP derived from winter flounder, an inhibition of macromolecular synthesis was reported in E. coli in the context of initial membrane depolarization (13) . In addition, effects on intracellular enzymes have already been described. For example, antimicrobial peptides derived from insects such as drosicin, apidaecin, and pyrrhocidin affect bacterial heat-shock proteins (56) . They interact in a specific manner with the 70-kDa DnaK chaperone and in a nonspecific manner with the 60-kDa chaperonin GroEL. Thereby, they inhibit their ATPase activity and prevent chaperoneassisted protein folding (14, 47) . peptide LL-37-induced chemotactic effects in vitro, triggering selective migration of human peripheral blood monocytes, neutrophils, and CD4 T-cells.
Intracellular localization of SP1-1
The in vivo tests with the ⌬sigB deletion mutants of S. aureus already provided evidence that SP1-1 enters the bacteria cells. Intracellular localization of SP1-1 in S. aureus was verified by nanoSIMS technology using 15 N-labeled SP1-1. The nanoSIMS technology is based on the mass spectrometry of secondary ions, extracted from surface layers of the sample under the impact of an energetic ion beam. In detail, a beam of ions is scanned across single bacteria cells. In this way, the bacterial cell is sputtered layer by layer into atoms and atomic clusters, and the extracted secondary ions are identified by a magnetic sector mass spectrometer (57 14 N was analyzed for single bacterial cells (Fig. 4) . Images of all collected secondary electrons and MS images of Fig. S1 ). The images of the secondary electrons make single bacterial cells visible on the filter (Fig. 4A and Supplemental Fig. S1 ). The 12 C Ϫ signal shows the polycarbonate filter, where the cells were fixed. A 32 S Ϫ signal served as marker for proteins and organic material and colocalized with the analyzed cells. 16 O Ϫ and 13 C Ϫ levels were very low or nondetectable, confirming that bacterial cells were present and no other particles or artifacts (Supplemental Fig. S1 ). Signals from natural 14 N represent bacterial nitrogencontaining compounds colocalized with the 15 N signals (Fig. 4B) . After 10 min incubation, some bacterial cells already showed an intracellular accumulation of SP1-1, with some bacterial cells showing very high enrichments up to the 13th fold of the background (Fig. 4C,  D) . The signals were still detectable after 30 min of treatment (Fig. 4E, F) , showing a more balanced enrichment with no extreme outliers. A boxplot of 12 C 15 N Ϫ / 12 C 14 N Ϫ ratios derived from regions of interest on bacterial cells is shown in Fig. 4G .
Effect of SP1-1 on gene expression in S. aureus
Under stress conditions, RsbW binds to the nonphosphorylated RsbV and releases SigB. The transcription factor thereupon interacts with the core RNA polymerase and initiates transcription of genes involved in capsulated polysaccharide synthesis or with functions related to the cell envelope, such as autolysin and several transporters (54) . Furthermore, the regulation of several virulence-associated genes, for example, adhesins, exoproteins, and different toxins, are SigB dependent (58) . Phosphatase RsbU acts as a further part of this dynamic system. It dephosphorylates RsbV, resulting in binding of RsbW to RsbV and release of the transcription factor from the kinase (36) . Perturbation of this regulatory network can have strong effects on gene expression and thereby on growth or infectivity (59, 60) .
Since SP1-1 affects the RsbW-SigB transcription system, its effect on gene expression was investigated by microarray analysis. The S. aureus oligoarray used covered 95% of the whole S. aureus COL genome with its 10,807 60-mer oligoprobes (23) . For microarray analysis, a sublethal concentration of SP1-1 was performed (Supplemental Fig. S2 ). A total of 106 genes showed Ͼ3-fold changes in their expression levels. Sixteen genes were up-regulated (Table 1) , and 90 genes were down-regulated (Supplemental Table S1 ). The 16 induced genes have functions in cell wall metabolism (atl, lytM, sceD), oxidative phosphorylation (cytochrome d ubiquinol oxidase), biofilm formation (icaA, icaB, icaD), and virulence (staphyloxanthin biosynthesis, ssaA). The repressed genes include several vra genes (vraD, vraE, vraF) encoding for transport proteins influencing resistance to antibiotics (22) , as well as many ABC transporters for maltose, Functional categories (after http://www.ncbi.nlm.nih.gov/COG/grace/fiew.cgi?gϭ158879): C, energy production and conservation; E, amino acid transport and metabolism; G, carbohydrate transport and metabolism; I, lipid transport and metabolism; M, cell wall/membrane/ envelope biogenesis; R, general function only predicted; Q, secondary metabolite synthesis, transport, and catabolism. Peptides (SP1-1 and SP8; 10 -400 ng) were incubated with 100 ng of bacterial plasmid DNA at room temperature for 1 h, and the reaction mixtures were applied to 1% agarose gel electrophoresis. weight ratio (peptide/DNA) is indicated. BSA (400 g/ml) was used as control.
peptides, and amino acids. Furthermore, genes involved in biosynthesis of amino acids, such as histidine, lysine, and glutamate, are repressed. Influencing the function of RsbW can have a large effect on SigB-dependent transcription in S. aureus. This alternative transcription factor has influence on resistance of S. aureus to multiple stresses, such as heat, alkaline and acidic shock, hydrogen peroxide, pulsed electric fields, and high hydrostatic pressure (61) . In a comparative microarray analysis of wild-type and ⌬sigB strains, a total number of 251 SigB-dependent genes was detected, whereas 198 are positively and 53 negatively regulated by SigB (58) . In another study, the comparison of WT and ⌬sigB strains revealed that SigB has an activating effect on the expression of 122 genes under alkaline stress conditions (54) .
SP1-1 induced the virulence determinant ssaA and the putative transglycosylase sceD, which are both positively regulated by SigB (58, 62) . Many genes with functions in cell wall envelope are also SigB dependent, e.g., autolysin Atl (54). Furthermore, genes from the ica operon were also up-regulated by SP1-1. This operon functions in biofilm formation (63) . At least icaA is positively regulated by SigB in S. epidermis (64) . Regulation of ica genes by SigB and Agr in S. aureus is also under discussion (65) . Moreover, it is known that SigB affects pigmentation and that S. aureus mutant strains, lacking SigB and its positive regulator RsbU, are unable to accumulate the pigment staphyloxanthin (53, 66) . Three genes encoding for proteins with function in staphyloxanthin biosynthesis (SACOL2291, SACOL2295, SACOL2581) were up-regulated by SP1-1. These 3 genes were classified to be positively SigB dependent (54) . Furthermore, SigB negatively regulates several genes involved in amino acid or peptide transport (SACOL2441, SACOL2471-SACOL2476) (54) . These genes were also down-regulated by SP1-1. The same was observed for iron compound ABC transporter gene sirA (SACOL0099). However, a clear hyperactivation of SigB-dependent transcription could not be observed in the microarray analysis. Probably this effect is covered by effects of direct DNA binding activity of SP1-1. DNA-binding activity of SP1-1 has been demonstrated in a gel retardation experiment (Fig. 5) .
Interestingly, 6 of the 16 SP1-1-induced genes have a binding motive for WalR proteins (Table 1) . WalR proteins are part of the WalK/WalR 2-component signal transduction system (TCS), which plays a key role in cell wall metabolism and is essential for the viability of S. aureus (67) . These 6 genes include the cell wall degradation/turnover genes sle1, ssaA, atlA, and lytM, whereas the latter 2 encode the two major S. aureus autolysins (AltA and LytM) (67, 68) . Probably SP1-1 directly activates the WalKR system. In an S. aureus mutant strain expressing a constitutively active WalR protein, 10 genes containing a WalR binding motif are induced (68) . Interestingly, 6 of these genes were also up-regulated after SP1-1 treatment. Although we cannot exclude the possibility that SP1-1 is acting on other factors, which might influence expression of these genes, this high overlap suggests a direct influence of SP1-1 on the WalKR TCS. Since genes involved in cell growth and pathogenicity are often controlled by TCSs, these systems are potential drug targets (69) . Inhibitors of such systems work differently from conventional antibiotics and therefore might be of special important for controlling multiresistant S. aureus strains.
CONCLUSIONS
The growing number of multiresistant S. aureus strains in addition to the absence of programs dedicated to new antibiotic discovery stimulate the search for alternative compounds showing antimicrobial activity. In this study, de novo-designed AMPs were tested for their anti-S. aureus activity, and their antibacterial mode of action was analyzed. We identified RsbW kinase as a target for our de novo-designed AMP SP1-1. Kinase inhibitors especially fulfill important functions in modern medicine regarding cancer or inflammation processes. In this context SP1-1 might serve as a very promising candidate for further studies to develop kinase inhibitors. But the effect on the WalKR 2-component signal transduction system as well could be an interesting starting point to develop efficient drugs against multiresistant S. aureus strains.
